Pfizer, Astellas win priority review for Xtandi sNDA; Hemispherx changes its name
→ The FDA has granted Pfizer $PFE and Astellas priority review for a label expansion for Xtandi, the prostate cancer drug it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
